Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Am J Hematol

Retrieve available abstracts of 194 articles:
HTML format

Single Articles

    November 2021
  1. FATTIZZO B, Giannotta JA, Cecchi N, Barcellini W, et al
    SARS-CoV-2 vaccination in patients with autoimmune cytopenias: The experience of a reference center.
    Am J Hematol. 2021;96:E413-E416.

  2. HENRY DH, Glaspy J, Harrup R, Mittelman M, et al
    Roxadustat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome: Open-label, Dose-selection, Lead-in Stage of a Phase 3 Study.
    Am J Hematol. 2021 Nov 1. doi: 10.1002/ajh.26397.
    PubMed     Abstract available

  3. KOUNTOURIS P, Stephanou C, Archer N, Bonifazi F, et al
    The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies.
    Am J Hematol. 2021;96:E416-E420.

  4. MARTIN ES, Ferrer A, Mangaonkar AA, Khan SP, et al
    Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
    Am J Hematol. 2021;96:1450-1460.
    PubMed     Abstract available

  5. LONGORIA JN, Pugh NL, Gordeuk V, Hsu LL, et al
    Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.
    Am J Hematol. 2021;96:1396-1406.
    PubMed     Abstract available

  6. MUSALLAM KM, Bou-Fakhredin R, Cappellini MD, Taher AT, et al
    2021 update on clinical trials in beta-thalassemia.
    Am J Hematol. 2021;96:1518-1531.
    PubMed     Abstract available

  7. HEBBEL RP, Vercellotti GM
    Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.
    Am J Hematol. 2021;96:1505-1517.
    PubMed     Abstract available

    October 2021
  8. MAKHARADZE T, Boccia R, Krupa A, Blackman N, et al
    Efficacy and Safety of Ferric Carboxymaltose Infusion in Reducing Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: a Randomized, Placebo-Controlled Study (IRON CLAD).
    Am J Hematol. 2021 Oct 15. doi: 10.1002/ajh.26376.
    PubMed     Abstract available

  9. COX HD, Miller GD, Manandhar A, Husk JD, et al
    Tracking immature reticulocyte proteins for improved detection of recombinant human erythropoietin (rhEPO) abuse.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26368.
    PubMed     Abstract available

  10. ASPERTI M, Brilli E, Denardo A, Gryzik M, et al
    Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
    Am J Hematol. 2021;96:1253-1263.
    PubMed     Abstract available

  11. DE MONTALEMBERT M, Voskaridou E, Oevermann L, Cannas G, et al
    Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    Am J Hematol. 2021;96:1223-1231.
    PubMed     Abstract available

  12. PIATTI G, Giuditta M, Pierini A, Consonni D, et al
    Muscular de-conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major.
    Am J Hematol. 2021;96:E370-E373.

    September 2021
  13. VIRK ZM, Patel AA, Leaf RK, Al-Samkari H, et al
    Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26359.
    PubMed     Abstract available

  14. PETIT AF, Kulasekararaj AG, Eikema DJ, Maschan A, et al
    Upfront unrelated donor Hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: a retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26354.

  15. MEZNARICH JA, Rets A, Agarwal AM, Christensen RD, et al
    Novel, De Novo, Beta-Globin Variant with Decreased Oxygen Affinity (HBB:C.317T>A, "Hemoglobin St. George") in a Healthy Child with Low Oxygen Saturations and Anemia.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26356.

  16. YE L, Jing L, Guo J, Zhao X, et al
    Red Blood Cell Lifespan is Reduced in Severe Aplastic Anemia and Improves with Response to Immunosuppressive Treatment.
    Am J Hematol. 2021 Sep 2. doi: 10.1002/ajh.26344.

  17. D'HUMIERES T, Savale L, Inamo J, Deux JF, et al
    Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis.
    Am J Hematol. 2021;96:1166-1175.
    PubMed     Abstract available

  18. ROGER C, Lionnet F, Mattioni S, Livrozet M, et al
    Risk factors for CKD stage II onset in a prospective cohort of homozygous sickle cell adults.
    Am J Hematol. 2021;96:1147-1155.
    PubMed     Abstract available

  19. MANSOUR-HENDILI L, Egee S, Monedero-Alonso D, Bouyer G, et al
    Multiple thrombosis in a patient with Gardos channelopathy and a new KCNN4 mutation.
    Am J Hematol. 2021;96:E318-E321.

  20. VAN VUREN AJ, Minniti CP, Mendelsohn L, Baird JH, et al
    Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease.
    Am J Hematol. 2021;96:E315-E318.

    August 2021
  21. PEREZ BOTERO J, Reese JA, George JN, McIntosh JJ, et al
    Severe Thrombocytopenia and Microangiopathic Hemolytic Anemia in Pregnancy: A Guide for the Consulting Hematologist.
    Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26328.
    PubMed     Abstract available

  22. DEXTER D, Layton DM, Kiritkumar K, Bain BJ, et al
    Peripheral blood features of iron overload in post-splenectomy, type I congenital dyserythropoietic anemia.
    Am J Hematol. 2021 Aug 20. doi: 10.1002/ajh.26327.

  23. SHIMANO KA, Narla A, Rose MJ, Gloude NJ, et al
    Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.
    Am J Hematol. 2021 Aug 3. doi: 10.1002/ajh.26310.
    PubMed     Abstract available

  24. PEREZ-LAMAS L, Moreno-Jimenez G, Tenorio-Nunez MC, Velazquez-Kennedy K, et al
    Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease.
    Am J Hematol. 2021;96:E288-E291.

  25. BOU-FAKHREDIN R, Daadaa H, Koussa S, Abou Nasr T, et al
    SARS-CoV-2 infection in patients with beta-thalassemia: Experience from Lebanon.
    Am J Hematol. 2021;96:E285-E288.

  26. HAYFRON-BENJAMIN CF, Asare EV, Boafor T, Olayemi E, et al
    Low FEV1 is associated with fetal death in pregnant women with sickle cell disease.
    Am J Hematol. 2021;96:E303-E306.

  27. EDJLALI M, Gobin-Metteil MP, Mele N, Maier B, et al
    Transcranial color-coded duplex sonography reliably identifies intracranial vasculopathy in adult patients with sickle cell disease.
    Am J Hematol. 2021;96:961-967.
    PubMed     Abstract available

  28. VU C, Bush A, Choi S, Borzage M, et al
    Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias.
    Am J Hematol. 2021;96:901-913.
    PubMed     Abstract available

  29. KNEE KM, Jasuja R, Barakat A, Rao D, et al
    PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease.
    Am J Hematol. 2021;96:E272-E275.

  30. MALECKA A, Troen G, Delabie J, Malecki J, et al
    The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels.
    Am J Hematol. 2021;96:E279-E283.

  31. JANKOVSKY N, Caulier A, Demagny J, Guitton C, et al
    Recent advances in the pathophysiology of PIEZO1-related hereditary xerocytosis.
    Am J Hematol. 2021;96:1017-1026.
    PubMed     Abstract available

  32. FAN BE, Cao L, Gallardo CA, Lee SMS, et al
    Myeloid and lymphoid vacuolation in VEXAS syndrome.
    Am J Hematol. 2021;96:1056-1057.

    July 2021
  33. HANSEN DL, Berentsen S, Fattizzo B, Hansen PL, et al
    Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy.
    Am J Hematol. 2021;96:E262-E265.

  34. WAHEED A, Kuter DJ
    Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Am J Hematol. 2021;96:E235-E237.

  35. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, et al
    Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
    Am J Hematol. 2021;96:E246-E249.

  36. KULASEKARARAJ AG, Brodsky RA, Hill A
    Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor.
    Am J Hematol. 2021;96:E232-E235.

    June 2021
  37. GURUNG K, Bain BJ
    A normal mean cell volume does not exclude a diagnosis of megaloblastic anemia.
    Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26283.

  38. KIRK SE, Scheurer ME, Bernhardt MB, Mahoney DH, et al
    Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Am J Hematol. 2021;96:E215-E218.

  39. PANAGIOTA V, Meggendorfer M, Kubasch AS, Gabdoulline R, et al
    Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
    Am J Hematol. 2021;96:E207-E210.

  40. ZHANG X, Yang Y, Zhang H, Du Z, et al
    A rare complex rearrangement in the beta-globin gene cluster causing a novel homozygous (G) gamma((A) gammadeltabeta)(0) -thalassemia.
    Am J Hematol. 2021;96:E189-E193.

    May 2021
  41. RAMIREZ MJ, Pujol R, Trujillo-Quintero JP, Minguillon J, et al
    Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients.
    Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26234.
    PubMed     Abstract available

  42. KIM SJ, Song J, Reading NS, Lautersztain J, et al
    Novel mechanism of hereditary pyropoikilocytosis phenotype due to co-inheritance of beta globin and alpha spectrin mutations.
    Am J Hematol. 2021;96:E150-E154.

  43. KALANTAR-ZADEH K, Ganz T, Trumbo H, Seid MH, et al
    Parenteral iron therapy and phosphorus homeostasis: A review.
    Am J Hematol. 2021;96:606-616.
    PubMed     Abstract available

  44. BAIN BJ
    Alpha chain inclusions in peripheral blood erythroblasts and erythrocytes.
    Am J Hematol. 2021;96:630-631.

    April 2021
  45. MAQUET J, Lafaurie M, Walter O, Sailler L, et al
    Epidemiology of autoimmune hemolytic anemia: a nationwide population-based study in France.
    Am J Hematol. 2021 Apr 30. doi: 10.1002/ajh.26213.

  46. BARCELLINI W, Zaninoni A, Giannotta JA, Merati G, et al
    Circulating extracellular vesicles and cytokines in congenital and acquired hemolytic anemias.
    Am J Hematol. 2021;96:E129-E132.

  47. MINNITI CP, Knight-Madden J, Tonda M, Gray S, et al
    The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
    Am J Hematol. 2021;96:E126-E128.

  48. AL-ALI AK, Alsulaiman A, Alfarhan M, Safaya S, et al
    Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features.
    Am J Hematol. 2021;96:E117-E121.

  49. MCGRATH M, Quint EH, Weyand AC
    Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting.
    Am J Hematol. 2021;96:E105-E108.

  50. ARCHULETA J, van der Graaf M, Kaptein FHJ, Althaus L, et al
    Sudden death due to massive bone marrow sequestration crisis in a patient with sickle cell disease.
    Am J Hematol. 2021;96:E100-E102.

  51. OSUNKWO I, Andemariam B, Minniti CP, Inusa BPD, et al
    Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
    Am J Hematol. 2021;96:404-417.
    PubMed     Abstract available

  52. LANZKRON S, Smith-Whitley K
    Swaying sickle cell research forward in support of patient reported outcomes.
    Am J Hematol. 2021;96:402-403.

    March 2021
  53. PATNAIK MM, Tefferi A
    Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
    Am J Hematol. 2021;96:379-394.
    PubMed     Abstract available

  54. DENTON CC, Shah P, Suriany S, Liu H, et al
    Loss of alpha-globin genes in human subjects is associated with improved nitric oxide-mediated vascular perfusion.
    Am J Hematol. 2021;96:277-281.
    PubMed     Abstract available

  55. MUSALLAM KM, Rivella S, Taher AT
    Management of non-transfusion-dependent beta-thalassemia (NTDT): The next 5 years.
    Am J Hematol. 2021;96:E57-E59.

    February 2021
  56. ZUBICARAY J, Pagliara D, Sevilla J, Eikema DJ, et al
    Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: results from the Severe Aplastic Anemia Working Party of the EBMT.
    Am J Hematol. 2021 Feb 19. doi: 10.1002/ajh.26135.
    PubMed     Abstract available

  57. ROMANA M, Reminy K, Moeckesch B, Charlot K, et al
    Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26126.

  58. AUERBACH M, Henry D, DeLoughery TG
    Intravenous ferric derisomaltose for the treatment of iron deficiency anemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26124.
    PubMed     Abstract available

  59. KARKOSKA K, Quinn CT, Niss O, Pfeiffer A, et al
    Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
    Am J Hematol. 2021 Feb 3. doi: 10.1002/ajh.26120.
    PubMed     Abstract available

  60. LEBENSBURGER JD, Aban I, Hilliard LM, Feig DI, et al
    Hyperuricemia and Abnormal Nocturnal Dipping Impact Glomerular Filtration Rate in Patients with Sickle Cell Anemia.
    Am J Hematol. 2021 Feb 1. doi: 10.1002/ajh.26115.

  61. MUSALLAM KM, Cappellini MD, Viprakasit V, Kattamis A, et al
    Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later.
    Am J Hematol. 2021;96:E54-E56.

  62. SCHMIDT PJ, Fitzgerald K, Butler JS, Fleming MD, et al
    Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
    Am J Hematol. 2021;96:251-257.
    PubMed     Abstract available

    January 2021
  63. LUNATI A, Petit A, Lapillonne H, Gameiro C, et al
    VPS4A mutation in syndromic congenital hemolytic anemia without obvious signs of dyserythropoiesis.
    Am J Hematol. 2021 Jan 18. doi: 10.1002/ajh.26099.

  64. GLADWIN MT, Kato GJ, Gordeuk VR
    Identifying adolescent and young adult patients with sickle cell disease at highest risk of death.
    Am J Hematol. 2021;96:9-11.

  65. RAB MAE, Kanne CK, Bos J, van Oirschot BA, et al
    Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.
    Am J Hematol. 2021;96:E29-E32.

  66. ROSANWO TO, Kean LS, Archer NM
    End the pain: Start with antiracism.
    Am J Hematol. 2021;96:4-6.

  67. OGU UO, Thomas M, Chan F, Vattappally L, et al
    L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality.
    Am J Hematol. 2021;96:E38-E40.

  68. CHALACHEVA P, Ji Y, Rosen CL, DeBaun MR, et al
    Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease.
    Am J Hematol. 2021;96:60-68.
    PubMed     Abstract available

  69. COSTA E, Tibalinda P, Sterzi E, Leufkens HMG, et al
    Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Am J Hematol. 2021;96:E2-E5.

  70. SHAH P, Suriany S, Kato R, Bush AM, et al
    Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups - revisiting this controversial concept after 16 years of additi
    Am J Hematol. 2021;96:31-39.
    PubMed     Abstract available

    December 2020
  71. KARKOSKA K, Quinn CT, Clapp K, McGann PT, et al
    Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.
    Am J Hematol. 2020;95:E338-E339.

  72. COHEN J, Khudanyan A, Lu J, Wing J, et al
    A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency.
    Am J Hematol. 2020;95:1572-1577.
    PubMed     Abstract available

    November 2020
  73. DAVIS BH
    Assay for "fetal hemoglobin levels" in erythrocytes: Impact of new In Vitro Diagnostics regulation and expanded applications in sickle cell disease management.
    Am J Hematol. 2020;95:1230-1232.

    Can any new thalassemia therapy achieve a better than 97.4% cure rate?
    Am J Hematol. 2020;95:1233-1234.

  75. HE Y, Jiang H, Li C, Zhu Y, et al
    Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: A multi-center large-sample study.
    Am J Hematol. 2020;95:E297-E299.

  76. RUSSO R, Marra R, Andolfo I, Manna F, et al
    Uridine treatment normalizes the congenital dyserythropoietic anemia type II-like hematological phenotype in a patient with homozygous mutation in the CAD gene.
    Am J Hematol. 2020;95:1423-1426.

  77. MERLET AN, Feasson L, Bartolucci P, Hourde C, et al
    Muscle structural, energetic and functional benefits of endurance exercise training in sickle cell disease.
    Am J Hematol. 2020;95:1257-1268.
    PubMed     Abstract available

  78. HEBERT N, Rakotoson MG, Bodivit G, Audureau E, et al
    Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
    Am J Hematol. 2020;95:1235-1245.
    PubMed     Abstract available

  79. KUCUKAL E, Man Y, Hill A, Liu S, et al
    Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease.
    Am J Hematol. 2020;95:1246-1256.
    PubMed     Abstract available

  80. DE CASTRO C, Grossi F, Weitz IC, Maciejewski J, et al
    C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
    Am J Hematol. 2020;95:1334-1343.
    PubMed     Abstract available

    October 2020
  81. POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
    Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
    PubMed     Abstract available

  82. ONALO R, Cooper P, Cilliers A, Vorster BC, et al
    Randomized Control Trial of Oral Arginine Therapy for Children with Sickle Cell Anemia Hospitalized for Pain in Nigeria.
    Am J Hematol. 2020 Oct 19. doi: 10.1002/ajh.26028.
    PubMed     Abstract available

  83. WOLF M, Auerbach M, Kalra PA, Glaspy J, et al
    Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials.
    Am J Hematol. 2020 Oct 7. doi: 10.1002/ajh.26015.

    September 2020
  84. DEBEER T, Jordan LC, Lee CA, Patel NJ, et al
    Evidence of transfusion-induced reductions in cerebral capillary shunting in sickle cell disease.
    Am J Hematol. 2020;95:E228-E230.

  85. SONI S
    Gene therapies for transfusion dependent beta-thalassemia: Current status and critical criteria for success.
    Am J Hematol. 2020;95:1099-1112.
    PubMed     Abstract available

  86. GALADANCI NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, et al
    Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
    Am J Hematol. 2020;95:E247-E250.

  87. GEORGE A, Dinu B, Estrada N, Minard CG, et al
    Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.
    Am J Hematol. 2020;95:E242-E244.

  88. KNISELY MR, Pugh N, Kroner B, Masese R, et al
    Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium.
    Am J Hematol. 2020;95:1066-1074.
    PubMed     Abstract available

  89. TISDALE JF, Pierciey FJ Jr, Bonner M, Thompson AA, et al
    Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
    Am J Hematol. 2020;95:E239-E242.

  90. SCARAMELLINI N, Consonni D, Cassinerio E, Arighi C, et al
    A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 mug/L.
    Am J Hematol. 2020;95:E230-E232.

  91. SIDANA S, Murray DL, Dasari S, Go RS, et al
    Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease.
    Am J Hematol. 2020;95:E222-E225.

  92. TSEU B, Siow W, Pushkaran B, Cheesebrough B, et al
    Beta thalassemia major and Noonan syndrome - Two genetic disorders manifest in the blood film.
    Am J Hematol. 2020;95:1113-1114.

    August 2020
  93. WILDING C, Pelling D, Lund K, Bain BJ, et al
    Erythrophagocytosis by monocytes - an unusual observation in autoimmune hemolytic anemia.
    Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25966.

  94. JORDAN LC, Rodeghier M, Donahue MJ, DeBaun MR, et al
    Reduction in TCD velocity after regular blood transfusion therapy is associated with a change in hemoglobin S fraction in sickle cell anemia.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25954.

  95. NAYMAGON L, Berwick S, Kessler A, Lancman G, et al
    The emergence of methemoglobinemia amidst the COVID-19 pandemic.
    Am J Hematol. 2020;95:E196-E197.

  96. TAHER AT, Bou-Fakhredin R, Kreidieh F, Motta I, et al
    Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations.
    Am J Hematol. 2020;95:E208-E210.

  97. KUIPERS MT, van Zwieten R, Heijmans J, Rutten CE, et al
    Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine.
    Am J Hematol. 2020;95:E194-E196.

  98. ODIEVRE MH, de Marcellus C, Ducou Le Pointe H, Allali S, et al
    Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.
    Am J Hematol. 2020;95:E192-E194.

  99. MOTTA I, Migone De Amicis M, Pinto VM, Balocco M, et al
    SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience.
    Am J Hematol. 2020;95:E198-E199.

  100. MITRA A, Dwyre DM, Schivo M, Thompson GR 3rd, et al
    Leukoerythroblastic reaction in a patient with COVID-19 infection.
    Am J Hematol. 2020;95:999-1000.

  101. MACRAE FL, Peacock-Young B, Bowman P, Baker SR, et al
    Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
    Am J Hematol. 2020;95:944-952.
    PubMed     Abstract available

  102. HARPER K, McIlwaine L, Leach M, Bain BJ, et al
    Giant proerythroblasts in pure red cell aplasia due to parvovirus B19 infection in a patient with rheumatoid arthritis.
    Am J Hematol. 2020;95:990-991.

    July 2020
  103. DOMINGUES-HAMDI E, Vasseur C, Pakdaman S, Moutereau S, et al
    Hydroxycarbamide decreases the free alpha-hemoglobin pool in red blood cells of adult patients with sickle cell anemia.
    Am J Hematol. 2020 Jul 28. doi: 10.1002/ajh.25947.

  104. GORDEUK VR, Shah BN, Zhang X, Thuma PE, et al
    CYB5R3(c) (.350C>G) and G6PD A Alleles Modify Severity of Anemia in Malaria and Sickle Cell Disease.
    Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25941.
    PubMed     Abstract available

  105. SONG AB, Kuter DJ, Al-Samkari H
    Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia.
    Am J Hematol. 2020 Jul 3. doi: 10.1002/ajh.25925.
    PubMed     Abstract available

  106. DE LUNA G, Habibi A, Deux JF, Colard M, et al
    Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.
    Am J Hematol. 2020;95:876-878.

  107. FAN BE, Ong KH, Chan SSW, Young BE, et al
    Blood and blood product use during COVID-19 infection.
    Am J Hematol. 2020;95:E158-E160.

  108. BEERKENS F, John M, Puliafito B, Corbett V, et al
    COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient.
    Am J Hematol. 2020;95:E154-E156.

  109. NOURAIE M, Darbari DS, Rana S, Minniti CP, et al
    Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.
    Am J Hematol. 2020;95:766-774.
    PubMed     Abstract available

  110. VAN TUIJN CFJ, Gaartman AE, Nur E, Rijneveld AW, et al
    Incentive spirometry to prevent acute chest syndrome in adults with sickle cell disease; a randomized controlled trial.
    Am J Hematol. 2020;95:E160-E163.

    June 2020
  111. ACHEBE MM, Glaspy J, Kalra PA, Auerbach M, et al
    A six month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25920.

  112. NUR E, Gaartman AE, van Tuijn CFJ, Tang MW, et al
    Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19).
    Am J Hematol. 2020;95:725-726.

  113. LIM SH, Dutta D
    Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease.
    Am J Hematol. 2020;95:E151-E153.

  114. HAUGHTON A, Stylian S, Bain BJ
    Stress erythropoiesis in hereditary spherocytosis.
    Am J Hematol. 2020;95:710-711.

    May 2020
  115. LOFARO T, Bain BJ
    Schistocytosis is not always microangiopathic hemolytic anemia.
    Am J Hematol. 2020 May 10. doi: 10.1002/ajh.25861.

  116. BIANCHI P, Fermo E, Lezon-Geyda K, van Beers EJ, et al
    Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency.
    Am J Hematol. 2020;95:472-482.
    PubMed     Abstract available

  117. SCHMIDT PJ, Hollowell ML, Fitzgerald K, Butler JS, et al
    Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
    Am J Hematol. 2020;95:492-496.
    PubMed     Abstract available

  118. ROUMENINA LT, Chadebech P, Bodivit G, Vieira-Martins P, et al
    Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy.
    Am J Hematol. 2020;95:456-464.
    PubMed     Abstract available

    Now I Am The Voice: "a journey of self-discovery through the eyes of a Thalassemic".
    Am J Hematol. 2020;95:E105-E107.

    April 2020
  120. PROCHASKA MT, Zhang H, Alavi C, Meltzer DO, et al
    Fatigability: A new perspective on and patient-centered outcome measure for patients with anemia.
    Am J Hematol. 2020 Apr 15. doi: 10.1002/ajh.25803.

  121. GIARDINO S, Peffault de Latour R, Aljurf M, Eikema DJ, et al
    Outcome of Patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective analysis on Behalf of EBMT group.
    Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25810.
    PubMed     Abstract available

  122. HWANG SR, O'Dowd T, Markovic SN, Wolanskyj-Spinner AP, et al
    Recurrent Checkpoint Inhibitor-Induced Warm Agglutinin Autoimmune Hemolytic Anemia in a Patient with Metastatic Melanoma.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25812.

  123. AL-BUBSEREE B, Leach M, Jones R, Bain BJ, et al
    The hematological effects of copper deficiency.
    Am J Hematol. 2020;95:446.

  124. ESPINOZA J, Shah P, Veluswamy S, Zeltzer L, et al
    Aura and mental stress are associated with reports of pain in sickle cell disease-a pilot study using a mobile application.
    Am J Hematol. 2020;95:E101-E103.

  125. DUTTA D, Li K, Methe B, Lim SH, et al
    Rifaximin on intestinally-related pathologic changes in sickle cell disease.
    Am J Hematol. 2020;95:E83-E86.

  126. VACLAVU L, Petr J, Petersen ET, Mutsaerts HJMM, et al
    Cerebral oxygen metabolism in adults with sickle cell disease.
    Am J Hematol. 2020;95:401-412.
    PubMed     Abstract available

  127. GONDELAUD F, Connes P, Nader E, Renoux C, et al
    Sialic acids rather than glycosaminoglycans affect normal and sickle red blood cell rheology by binding to four major sites on fibrinogen.
    Am J Hematol. 2020;95:E77-E80.

    March 2020
  128. MANARA R, Canna A, Caiazza M, Ponticorvo S, et al
    White matter volume changes in adult beta-thalassemia: negligible and unrelated to anemia and cognitive performances.
    Am J Hematol. 2020 Mar 20. doi: 10.1002/ajh.25790.

  129. CHOI S, Leahy RM, Wood JC
    Lower White Matter Volume in Beta-Thalassemia Associated with Anemia and Cognitive Performance.
    Am J Hematol. 2020 Mar 17. doi: 10.1002/ajh.25787.

  130. IKWUANUSI I, Jordan LC, Lee CA, Patel NJ, et al
    Cerebral hemodynamics and metabolism are similar in sickle cell disease patients with hemoglobin SS and Sbeta(0) thalassemia phenotypes.
    Am J Hematol. 2020;95:E66-E68.

  131. FOY BH, Li A, McClung JP, Ranganath R, et al
    Data-driven physiologic thresholds for iron deficiency associated with hematologic decline.
    Am J Hematol. 2020;95:302-309.
    PubMed     Abstract available

  132. ZHANG X, Shah BN, Zhang W, Saraf SL, et al
    S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease.
    Am J Hematol. 2020;95:E62-E65.

    February 2020
  133. SARNA K, Brittenham GM, Beall CM
    Current WHO hemoglobin thresholds for altitude and misdiagnosis of anemia among Tibetan highlanders.
    Am J Hematol. 2020 Feb 25. doi: 10.1002/ajh.25765.

  134. BELISARIO AR, de Almeida JA, Mendes FG, da Silva DMM, et al
    Prevalence and risk factors for albuminuria and glomerular hyperfiltration in a large cohort of children with sickle cell anemia.
    Am J Hematol. 2020 Feb 21. doi: 10.1002/ajh.25763.

  135. TOLU S, Reyes-Gil M, Ogu UO, Thomas M, et al
    Inherited High Fetal Hemoglobin in Sickle Cell Anemia: Outcomes with Aging High HbF and Sickle Cell.
    Am J Hematol. 2020 Feb 18. doi: 10.1002/ajh.25759.

  136. SCHECKEL CJ, Yanardag Acik D, Ravindran A, Marshall A, et al
    Hapticophagia: Tactile chew cravings in iron deficiency anemia.
    Am J Hematol. 2020 Feb 5. doi: 10.1002/ajh.25749.

  137. EATON WA
    Hemoglobin S polymerization and sickle cell disease: A retrospective on the occasion of the 70th anniversary of Pauling's Science paper.
    Am J Hematol. 2020;95:205-211.
    PubMed     Abstract available

  138. ANDOLFO I, Rosato BE, Manna F, De Rosa G, et al
    Gain-of-function mutations in PIEZO1 directly impair hepatic iron metabolism via the inhibition of the BMP/SMADs pathway.
    Am J Hematol. 2020;95:188-197.
    PubMed     Abstract available

  139. GENDREAU S, Scholer M, Cecchini J, Habibi A, et al
    Cerebral fat embolism in sickle cell disease.
    Am J Hematol. 2020;95:E41-E45.

    January 2020
  140. WALSH K, Blalock DV, Mehler PS
    Hematologic Findings in a Large Sample of Patients with Anorexia Nervosa and Bulimia Nervosa.
    Am J Hematol. 2020 Jan 15. doi: 10.1002/ajh.25732.

    Treating Sickle Cell Anemia: A New Era Dawns.
    Am J Hematol. 2020 Jan 10. doi: 10.1002/ajh.25724.

  142. WILLEN SM, McNeil JB, Rodeghier M, Kerchberger VE, et al
    Haptoglobin genotype predicts severe acute vaso-occlusive pain episodes in children with sickle cell anemia.
    Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25728.

  143. QASRAWI A, Arora R, Ramlal R, Munker R, et al
    Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
    Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25725.

  144. RICHARD F, van Lier JJ, Roubert B, Haboubi T, et al
    Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
    Am J Hematol. 2020;95:68-77.
    PubMed     Abstract available

  145. RAB MAE, Kanne CK, Bos J, Boisson C, et al
    Methodological aspects of the oxygenscan in sickle cell disease: A need for standardization.
    Am J Hematol. 2020;95:E5-E8.

  146. SCHYRR F, Dolci M, Nydegger M, Canellini G, et al
    Perioperative care of children with sickle cell disease: A systematic review and clinical recommendations.
    Am J Hematol. 2020;95:78-96.
    PubMed     Abstract available

  147. BAIN BJ
    Delta beta thalassemia.
    Am J Hematol. 2020;95:116.

    December 2019
  148. TRUDEL G, Shafer J, Laneuville O, Ramsay T, et al
    Characterizing the effect of exposure to microgravity on anemia, more space is worse.
    Am J Hematol. 2019 Dec 9. doi: 10.1002/ajh.25699.
    PubMed     Abstract available

  149. KAKO S, Kanda Y, Onizuka M, Aotsuka N, et al
    Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: a KSGCT prospective study.
    Am J Hematol. 2019 Dec 5. doi: 10.1002/ajh.25693.
    PubMed     Abstract available

  150. NEUBERG D
    Dissecting the web of ischemic stroke, sickle cell trait, and chronic kidney disease.
    Am J Hematol. 2019;94:1302.

    November 2019
  151. ATAGA KI, Wichlan D, Elsherif L, Derebail VK, et al
    A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.
    Am J Hematol. 2019;94:E299-E301.

  152. ANDOLFO I, Rosato BE, Marra R, De Rosa G, et al
    The BMP-SMAD pathway mediates the impaired hepatic iron metabolism associated with the ERFE-A260S variant.
    Am J Hematol. 2019;94:1227-1235.
    PubMed     Abstract available

  153. HALKES C, de Wreede LC, Knol C, Simand C, et al
    Allogeneic stem cell transplantation for acquired pure red cell aplasia.
    Am J Hematol. 2019;94:E294-E296.

    September 2019
  154. KARKI NR, Auerbach M
    Single total dose infusion of ferumoxytol (1020 mg in 30 minutes) is an improved method of administration of intravenous iron.
    Am J Hematol. 2019;94:E229-E231.

    August 2019
  155. BATHINI S, Holtzman NG, Koka R, Singh Z, et al
    Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.
    Am J Hematol. 2019;94:E216-E219.

  156. TAHER AT, Cappellini MD, Musallam KM
    Development of a thalassemia-related thrombosis risk scoring system.
    Am J Hematol. 2019;94:E207-E209.

    June 2019
  157. DETTERICH JA, Kato R, Bush A, Chalacheva P, et al
    Sickle cell microvascular paradox-oxygen supply-demand mismatch.
    Am J Hematol. 2019;94:678-688.
    PubMed     Abstract available

  158. DUTTA D, Methe BA, Morris A, Lim SH, et al
    Effects of rifaximin on circulating aged neutrophils in sickle cell disease.
    Am J Hematol. 2019;94:E175-E176.

  159. NANKANJA R, Kadhumbula S, Tagoola A, Geisberg M, et al
    HemoTypeSC Demonstrates >99% Field Accuracy in a Sickle Cell Disease Screening Initiative in Children of Southeastern Uganda.
    Am J Hematol. 2019;94:E164-E166.

  160. DUTTA D, Methe B, Morris A, Lim SH, et al
    Elevated urinary 3-indoxyl sulfate in sickle cell disease.
    Am J Hematol. 2019;94:E162-E164.

  161. ITZEP NP, Jadhav SP, Kanne CK, Sheehan VA, et al
    Spontaneous healing of avascular necrosis of the femoral head in sickle cell disease.
    Am J Hematol. 2019;94:E160-E162.

    May 2019
  162. BRUNSON A, Keegan T, Mahajan A, White R, et al
    High Incidence of Venous Thromboembolism Recurrence in Patients with Sickle Cell Disease.
    Am J Hematol. 2019 May 9. doi: 10.1002/ajh.25508.
    PubMed     Abstract available

  163. RAB MAE, van Oirschot BA, Bos J, Merkx TH, et al
    Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
    Am J Hematol. 2019;94:575-584.
    PubMed     Abstract available

  164. VINER M, Zhou J, Allison D, Han J, et al
    The morbidity and mortality of end stage renal disease in sickle cell disease.
    Am J Hematol. 2019;94:E138-E141.

  165. WALKER AL, Gaydos LM, Farzan R, De Castro L, et al
    Social media discussions provide new insight about perceptions of hydroxyurea in the sickle cell community.
    Am J Hematol. 2019;94:E134-E136.

  166. WEISS M, Parisi Jun M, Sheth S
    Clinical and economic burden of regularly transfused adult patients with beta-thalassemia in the United States: A retrospective cohort study using payer claims.
    Am J Hematol. 2019;94:E129-E132.

    Erythrocyte ATP, a possible therapeutic approach for sickle cell disease.
    Am J Hematol. 2019;94:E117.

  168. BAO EL, Lareau CA, Brugnara C, Fulcher IR, et al
    Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort.
    Am J Hematol. 2019;94:522-527.
    PubMed     Abstract available

    April 2019
  169. CHAI Y, Bush AM, Coloigner J, Nederveen AJ, et al
    White matter has impaired resting oxygen delivery in sickle cell patients.
    Am J Hematol. 2019;94:467-474.
    PubMed     Abstract available

  170. KIM TO, Grimes AB, Kirk S, Arulselvan A, et al
    Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review.
    Am J Hematol. 2019;94:461-466.
    PubMed     Abstract available

  171. TAHER AT, Origa R, Perrotta S, Kouraklis A, et al
    Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.
    Am J Hematol. 2019;94:E96-E99.

  172. OYEDEJI C, Strouse JJ, Crawford RD, Garrett ME, et al
    A multi-institutional comparison of younger and older adults with sickle cell disease.
    Am J Hematol. 2019;94:E115-E117.

  173. LEBENSBURGER JD, Aban I, Pernell B, Kasztan M, et al
    Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.
    Am J Hematol. 2019;94:417-423.
    PubMed     Abstract available

  174. ALLY M, Magesa P, Luzzatto L
    High frequency of acquired aplastic anemia in Tanzania.
    Am J Hematol. 2019;94:E86-E88.

  175. REES C, Lund K, Bain BJ
    Infantile pyknocytosis.
    Am J Hematol. 2019;94:489-490.

    March 2019
  176. JORDAN LC, Juttukonda MR, Kassim AA, DeBaun MR, et al
    Haploidentical bone marrow transplantation improves cerebral hemodynamics in adults with sickle cell disease.
    Am J Hematol. 2019 Mar 5. doi: 10.1002/ajh.25455.

  177. VERCELLOTTI GM, Dalmasso AP, Schaid TR Jr, Nguyen J, et al
    Critical role of C5a in sickle cell disease.
    Am J Hematol. 2019;94:327-337.
    PubMed     Abstract available

  178. CASALE M, Filosa A, Ragozzino A, Amendola G, et al
    Long-term improvement in cardiac magnetic resonance in beta-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.
    Am J Hematol. 2019;94:312-318.
    PubMed     Abstract available

  179. RODGERS GM, Kurtti AL, Gilreath JA
    Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
    Am J Hematol. 2019;94:394-395.

    February 2019
  180. MARSHALL AL, Mann S, Wolanskyj-Spinner A
    Digital storytelling for hematology education: Interactive thalassemia module for graduate millennial learners.
    Am J Hematol. 2019;94:E66-E67.

  181. DESAI PC, Kendel N, Huang Y, Heinlein M, et al
    Hypoxia in sickle cell disease due to right to left shunting.
    Am J Hematol. 2019;94:E53-E55.

  182. OPPONG SA, Asare EV, Olayemi E, Boafor T, et al
    Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting.
    Am J Hematol. 2019;94:223-230.
    PubMed     Abstract available

  183. GURUPRASAD P, Mannino RG, Caruso C, Zhang H, et al
    Integrated automated particle tracking microfluidic enables high-throughput cell deformability cytometry for red cell disorders.
    Am J Hematol. 2019;94:189-199.
    PubMed     Abstract available

  184. EISENGA MF, Wouters HJCM, Kieneker LM, van der Klauw MM, et al
    Active smoking and macrocytosis in the general population: Two population-based cohort studies.
    Am J Hematol. 2019;94:E45-E48.

  185. TAHER A, Viprakasit V, Cappellini MD, Sutcharitchan P, et al
    Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO((c)) ).
    Am J Hematol. 2019;94:171-176.
    PubMed     Abstract available

  186. SHARARA AI, Rustom LBO, Marrache M, Rimmani HH, et al
    Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia.
    Am J Hematol. 2019;94:E43-E45.

  187. TAHER A, Cappellini MD, Viprakasit V, Sutcharitchan P, et al
    Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO((c)) ).
    Am J Hematol. 2019;94:177-183.
    PubMed     Abstract available

    January 2019
  188. KRISHNAMURTI L, Neuberg DS, Sullivan KM, Kamani NR, et al
    Bone Marrow Transplantation for Adolescents and Young Adults with Sickle Cell Disease: Results of a Prospective Multicenter Pilot Study.
    Am J Hematol. 2019 Jan 13. doi: 10.1002/ajh.25401.
    PubMed     Abstract available

  189. BIANCHI P, Fermo E, Glader B, Kanno H, et al
    Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency.
    Am J Hematol. 2019;94:149-161.
    PubMed     Abstract available

  190. HAN J, Saraf SL, Molokie RE, Gordeuk VR, et al
    Use of metformin in patients with sickle cell disease.
    Am J Hematol. 2019;94:E13-E15.

  191. HAN J, Saraf SL, Gowhari M, Jain S, et al
    High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.
    Am J Hematol. 2019;94:E5-E7.

  192. CHAPMAN MS, Kiritkumar K, Lund K, Bain BJ, et al
    An unusual hemoglobinopathy: compound heterozygosity for hemoglobins C and E.
    Am J Hematol. 2019;94:144.

  193. KUTLAR A, Kanter J, Liles DK, Alvarez OA, et al
    Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Am J Hematol. 2019;94:55-61.
    PubMed     Abstract available

  194. STEELE C, Sinski A, Asibey J, Hardy-Dessources MD, et al
    Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.
    Am J Hematol. 2019;94:39-45.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.